BioSpace News Archive

Medivir AB announced the details of its upcoming phase 1/2a combination study with the company’s leading candidate drug, MIV-818, against liver cancer.

Unity HA announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Pulsante® SPG Microstimulator System for the treatment of acute pain associated with chronic cluster headaches.

Attendees are invited to register here to ensure you are able to attend the conference and receive any updates that are released.

Dynarex Corporation, a leading durable medical equipment and disposable medical products company, is pleased to announce its innovative new line of premium respiratory products—Dynarex Resp-O2™

Cellaria Inc (Wakefield, MA, USA), a scientific innovator with breakthrough tools for cancer research, now offers five stable, fully authenticated lung cancer cell models to support the development of more effective and targeted drug therapies.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, and Laurens Kruidenier, CSO, will present at the Jefferies Virtual Healthcare Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference

Kadmon Holdings, Inc. announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences

Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, are scheduled to present at the following conferences: